Cargando…
Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy
SIMPLE SUMMARY: Despite the great achievements of cancer immunotherapy in a variety of tumors, tumor heterogeneity and drug resistance still plague patients and clinical researchers. In particular, the occurrence of immune-related adverse events forces patients to discontinue cancer immunotherapy. T...
Autores principales: | Dai, Zhujiang, Fu, Jihong, Peng, Xiang, Tang, Dong, Song, Jinglue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564057/ https://www.ncbi.nlm.nih.gov/pubmed/36230724 http://dx.doi.org/10.3390/cancers14194796 |
Ejemplares similares
-
Intestinal microbiota: a new force in cancer immunotherapy
por: Dai, Zhujiang, et al.
Publicado: (2020) -
Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy
por: Davis, Lindy, et al.
Publicado: (2021) -
A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics
por: Zhang, Jie, et al.
Publicado: (2021) -
What are the Driving Forces Behind Spanish Publishers?
por: Magadán-Díaz, Marta, et al.
Publicado: (2022) -
Re-evaluating the driving force behind mutations
por: Leroy, Thibault
Publicado: (2023)